Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 12, 2004, Pages 1269-1276

  Herrlinger, K R ^a   Fellermann, K ^a   Fischer, C ^b   Kreisel, W ^c   Deibert, P ^c   Schoelmerich, J ^d   Fleig, W E ^e   Ruhl, A ^f   Reinshagen, M ^g   Greinwald, R ^h   Stange, E F ^a   Schwab, M ^b  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

^h Dr Falk Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ADULT; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DOSE RESPONSE; DRUG EFFICACY; ERYTHROCYTE; FEMALE; HUMAN; LEUKOPENIA; MALE; NODULAR HYPERPLASIA; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADULT; BIOLOGICAL MARKERS; CROHN DISEASE; DRUG MONITORING; ERYTHROCYTES; FEMALE; GUANINE NUCLEOTIDES; HUMANS; MALE; METHYLATION; MIDDLE AGED; REMISSION INDUCTION; THIOGUANINE; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 3042748324     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01947.x     Document Type: Article

References (43)

1. Elion GB. The purine path to chemotherapy. Science 1989; 244: 41-7.
2. Somerville L, Krynetski EY, Krynetskaia NF, et al. Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem 2003; 278: 1005-11.
3. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-45.
4. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-42.
5. Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003; 22: 7403-13.
6. Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol 1995; 47: 1141-7.
7. Belaiche J, Desager JP, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001; 36: 71-6.
8. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-6.
9. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6.
10. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
11. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
12. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70.
13. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003; 3(Suppl. 1): S30-8.
14. Bloomfeld RS, Onken JE. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther 2003; 17: 69-73.
15. Brox LW, Birkett L, Belch A. Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol 1981; 6: 35-8.
16. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993; 68: 186-90.
17. Lancaster DL, Patel N, Lennard L, Lilleyman JS. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 2002; 50: 33-6.
18. Harms DO, Gobel U, Spaar HJ, et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 2003; 102: 2736-40.
19. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998; 42: 266-72.
20. Lancaster DL, Lennard L, Rowland K, Vora AJ, Lilleyman JS. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol 1998; 102: 439-43.
21. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7: 181-9.
22. Herrlinger KR, Kreisel W, Schwab M, et al. 6-Thioguanine - efficacy and safety in chronic active Crohn's disease. Aliment Pharmacol Ther 2003; 17: 503-8.
23. Herrlinger KR, Deibert P, Schwab M, et al. Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1459-64.
24. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003; 98: 1058-63.
25. Derijks LJ, de Jong DJ, Gilissen LP, et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003; 15: 63-7.
26. Bonaz B, Boitard J, Marteau P, et al. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003; 18: 401-8.
27. Kroplin T, Weyer N, Gutsche S, Iven H. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 1998; 54: 265-71.
28. Schwab M, Schaffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-36.
29. Schaeffeler E, Lang T, Zanger UM, Eichelbaum M, Schwab M. High-throughput genotyping of thiopurine S-methyl-transferase by denaturing HPLC. Clin Chem 2001; 47: 548-55.
30. Iven H. Methylation of 6-mercaptopurine and 6-thioguanine in renal transplant recipients on azathioprine treatment. In: Kuhlmann, J. Klotz, U, eds. Clinical Pharmacology, Vol. 14.
31. Clinical Pharmacology and Oncology. München: Zuckschwerdt, 1996: 89-95.
32. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999; 117: 527-35.
33. Rowland K, Lennard L, Lilleyman JS. High-performance liquid chromatographic assay of methylthioguanine nucleotide. J Chromatogr B Biomed Sci Appl 1998; 705: 29-37.
34. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89-98.
35. Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M. Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only. Gastroenterology 2001; 121: 498-9.
36. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-2.
37. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
38. Stork LC, Broxson EH, Sather H, et al. Oral 6-thioguanine causes late onset splenomegaly and portal hypertension in a subset of children with acute lymphoblastic leukaemia (abstract). Gastroenterology 2002; 122: A833.
39. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125: 298-303.
40. Allan PW, Bennett LL Jr. 6-Methylthioguanylic acid, a metabolite of 6-thioguanine. Biochem Pharmacol 1971; 20: 847-52.
41. Dervieux T, Blanco JG, Krynetskl EY, Vanin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyl-transferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001; 61: 5810-6.
42. Tidd DM, Paterson AR. Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974; 34: 733-7.
43. Herrlinger KR, Schwab M, Fellermann K, Stange EF. 6-Thioguanine-buried alive? Gastroenterology 2004; 126: 940-1.